BioHealth News

CEL-SCI Announces Closing of Public Offering

CEL-SCI Announces Closing of Public Offering

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its underwritten…

Read More
USM Chancellor Jay Perman: The Reasons for Undergraduate Research

USM Chancellor Jay Perman: The Reasons for Undergraduate Research

University research has grabbed plenty of headlines over the past few months. Not for the breakthroughs that propel so much of American innovation. Not…

Read More
Senseonics Raises $77.8M Through Public Offering and Private Placement

Senseonics Raises $77.8M Through Public Offering and Private Placement

GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of…

Read More
ReGelTec Receives CE Mark for HYDRAFIL® System to Treat Chronic Low Back Pain

ReGelTec Receives CE Mark for HYDRAFIL® System to Treat Chronic Low Back Pain

CE Mark approval for the HYDRAFIL System was granted based on a clinical study of 75 patients that showed that those treated with HYDRAFIL…

Read More
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

ASHBURN, Va., May 22, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused…

Read More
GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale

GeneDx Publishes Pioneering Vision for Applying AI to Genomics to Improve and Expedite Diagnosis of Genetic Disease at Scale

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the publication of a new article in…

Read More
HHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent — BHI CEO Rich Bendis shares insights with the Washington Business Journal

HHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent — BHI CEO Rich Bendis shares insights with the Washington Business Journal

By Sara Gilgore – Staff Reporter, Washington Business Journal - May 21, 2025 - Once the Department of Health and Human Services unveiled a…

Read More
June 10, 2025 Webinar: Turning Uncertainty to Opportunity: Mastering Government Funding in 2025

June 10, 2025 Webinar: Turning Uncertainty to Opportunity: Mastering Government Funding in 2025

Navigating the Shifting Federal Funding Landscape Strategies, Insights, and AI-Driven Approaches for Winning Non-Dilutive Capital The federal funding landscape is undergoing a significant transformation.…

Read More
Ashburn’s Quoin Pharma’s QRX003 Granted Orphan Drug Status in Europe for Netherton Syndrome

Ashburn’s Quoin Pharma’s QRX003 Granted Orphan Drug Status in Europe for Netherton Syndrome

ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company…

Read More
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

ROCKVILLE, Md., May 19, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250 million with Healthcare…

Read More
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)

GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced…

Read More
Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement

Senseonics Announces Commencement of $50 Million Public Offering of Common Stock and Concurrent Private Placement

GERMANTOWN, Md., May 15, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing…

Read More
VPM: Mark Esser wants to make Charlottesville the Silicon Valley of biotech

VPM: Mark Esser wants to make Charlottesville the Silicon Valley of biotech

By Phil Liles: The University of Virginia has named Mark Esser as the first chief scientific officer of the upcoming Paul and Diane Manning Institute…

Read More
FDA Accepts REGENXBIO’s Application for Priority Review of Gene Therapy for Hunter Syndrome (MPS II)

FDA Accepts REGENXBIO’s Application for Priority Review of Gene Therapy for Hunter Syndrome (MPS II)

ROCKVILLE, Md., May 13, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA)…

Read More
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases,…

Read More